# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Belite Bio entered into a securities purchase agreement with an institutional investor, for the purchase and sale of up to an a...
HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and maintains $59 price target.
Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage biopharmaceutical drug developm...
HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $59 price target.
Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.30) by...
HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $59 price target.
Maxim Group analyst Jason McCarthy initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Targ...
Belite Bio, Inc (NASDAQ:BLTE), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeut...